News from the FDA/CDC

FDA Approves 10th Humira Biosimilar, With Interchangeability


 

The US Food and Drug Administration has approved the first interchangeable, high-concentration, citrate-free adalimumab biosimilar, adalimumab-ryvk (Simlandi).

This is the 10th adalimumab biosimilar approved by the regulatory agency and the first biosimilar approval in the US market for the Icelandic pharmaceutical company Alvotech in partnership with Teva Pharmaceuticals.

“An interchangeable citrate-free, high-concentration biosimilar adalimumab has the potential to change the market dynamics in a rapidly evolving environment for biosimilars in the U.S.,” said Robert Wessman, chairman and CEO of Alvotech, in a company press release on February 23.

Adalimumab-ryvk was approved in the European Union in 2021 and in Australia and Canada in 2022.

Adalimumab-ryvk is indicated for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, plaque psoriasis, hidradenitis suppurativa, and noninfectious intermediate and posterior uveitis and panuveitis. In pediatric patients, it is indicated for polyarticular juvenile idiopathic arthritis in children 2 years of age and older and Crohn’s disease in children 6 years of age and older.

Adalimumab-ryvk is the third Humira biosimilar overall granted interchangeability status, which allows pharmacists (depending on state law) to substitute the biosimilar for the reference product without involving the prescribing clinician. Adalimumab-adbm (Cyltezo), manufactured by Boehringer Ingelheim, and adalimumab-afzb (Abrilada), manufactured by Pfizer, were previously granted interchangeability status; however, they both are interchangeable with the low-concentration formulation of Humira, which make up only an estimated 15% of Humira prescriptions, according to a report by Goodroot.

Adalimumab-ryvk will be launched “imminently” in the United States, according to the press release, but no specific dates were provided. It is also not yet known how the biosimilar will be priced compared with Humira. Other adalimumab biosimilars have launched with discounts from 5% to 85% of Humira’s list price.

A version of this article appeared on Medscape.com.

Recommended Reading

FDA approves new formulation of Hyrimoz adalimumab biosimilar
Clinician Reviews
Meta-analysis examines cancer risk concern for JAK inhibitors
Clinician Reviews
Researchers seek to understand post-COVID autoimmune disease risk
Clinician Reviews
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
Clinician Reviews
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Clinician Reviews
Low-dose steroids may not increase cardiovascular risk in rheumatoid arthritis
Clinician Reviews
Approximately 20% of U.S. adults are diagnosed with arthritis
Clinician Reviews
Review estimates acne risk with JAK inhibitor therapy
Clinician Reviews
Study takes fine-grained look at MACE risk with glucocorticoids in RA
Clinician Reviews
Corticosteroid Injections Don’t Move Blood Sugar for Most
Clinician Reviews